Hubbry Logo
NeuromodulationNeuromodulationMain
Open search
Neuromodulation
Community hub
Neuromodulation
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Neuromodulation
Neuromodulation
Neuromodulation
View on Wikipedia
from Wikipedia

Neuromodulation is the physiological process by which a given neuron uses one or more chemicals to regulate diverse populations of neurons. Neuromodulators typically bind to metabotropic, G-protein coupled receptors (GPCRs) to initiate a second messenger signaling cascade that induces a broad, long-lasting signal. This modulation can last for hundreds of milliseconds to several minutes. Some of the effects of neuromodulators include altering intrinsic firing activity,[1] increasing or decreasing voltage-dependent currents,[2] altering synaptic efficacy, increasing bursting activity[2] and reconfiguring synaptic connectivity.[3]

Illustration of the brain and spinal cord connecting to a muscle, illustrating the connection between the central and peripheral nervous system.

Major neuromodulators in the central nervous system include: dopamine, serotonin, acetylcholine, histamine, norepinephrine, nitric oxide, and several neuropeptides. Cannabinoids can also be powerful CNS neuromodulators.[4][5][6] Neuromodulators can be packaged into vesicles and released by neurons, secreted as hormones and delivered through the circulatory system.[7] A neuromodulator can be conceptualized as a neurotransmitter that is not reabsorbed by the pre-synaptic neuron or broken down into a metabolite. Some neuromodulators end up spending a significant amount of time in the cerebrospinal fluid (CSF), influencing (or "modulating") the activity of several other neurons in the brain.[8]

Neuromodulator systems

[edit]
See also: Neural pathways

The major neurotransmitter systems are the noradrenaline (norepinephrine) system, the dopamine system, the serotonin system, and the cholinergic system. Drugs targeting the neurotransmitter of such systems affect the whole system, which explains the mode of action of many drugs.[citation needed]

Most other neurotransmitters, on the other hand, e.g. glutamate, GABA and glycine, are used very generally throughout the central nervous system.

Neuromodulator systems
System Origin[9] Targets[9] Effects[9]
Noradrenaline system Locus coeruleus Adrenergic receptors in:
  • arousal (Arousal is a physiological and psychological state of being awake or reactive to stimuli)
  • reward system
Lateral tegmental field
Dopamine system Dopamine pathways: Dopamine receptors at pathway terminations.
Serotonin system caudal dorsal raphe nucleus Serotonin receptors in:
rostral dorsal raphe nucleus Serotonin receptors in:
Cholinergic system Pedunculopontine nucleus and dorsolateral tegmental nuclei (pontomesencephalotegmental complex) (mainly) M1 receptors in:
basal optic nucleus of Meynert (mainly) M1 receptors in:
medial septal nucleus (mainly) M1 receptors in:

Noradrenaline system

[edit]
Further information: Norepinephrine § Norepinephrine system
Skeletal formulae diagram of Noradrenaline

The noradrenaline system consists of around 15,000 neurons, primarily in the locus coeruleus.[12] This is diminutive compared to the more than 100 billion neurons in the brain. As with dopaminergic neurons in the substantia nigra, neurons in the locus coeruleus tend to be melanin-pigmented. Noradrenaline is released from the neurons, and acts on adrenergic receptors. Noradrenaline is often released steadily so that it can prepare the supporting glial cells for calibrated responses. Despite containing a relatively small number of neurons, when activated, the noradrenaline system plays major roles in the brain including involvement in suppression of the neuroinflammatory response, stimulation of neuronal plasticity through LTP, regulation of glutamate uptake by astrocytes and LTD, and consolidation of memory.[13]

Dopamine system

[edit]
Further information: Dopamine § Functions in the brain

The dopamine or dopaminergic system consists of several pathways, originating from the ventral tegmentum or substantia nigra as examples. It acts on dopamine receptors.[14]

Skeletal formulae diagram of Dopamine

Parkinson's disease is at least in part related to dropping out of dopaminergic cells in deep-brain nuclei, primarily the melanin-pigmented neurons in the substantia nigra but secondarily the noradrenergic neurons of the locus coeruleus. Treatments potentiating the effect of dopamine precursors have been proposed and effected, with moderate success.[citation needed]

Dopamine pharmacology

[edit]

Serotonin system

[edit]
Further information: Serotonin § Gross anatomy
Skeletal formulae of Serotonin or 5-HT

The serotonin created by the brain comprises around 10% of total body serotonin. The majority (80-90%) is found in the gastrointestinal (GI) tract.[15][16] It travels around the brain along the medial forebrain bundle and acts on serotonin receptors. In the peripheral nervous system (such as in the gut wall) serotonin regulates vascular tone.[citation needed]

Serotonin pharmacology

[edit]
  • Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are widely used antidepressants that specifically block the reuptake of serotonin with less effect on other transmitters.[17][18][19]
  • Tricyclic antidepressants also block reuptake of biogenic amines from the synapse, but may primarily affect serotonin or norepinephrine or both. They typically take four to six weeks to alleviate any symptoms of depression. They are considered to have immediate and long-term effects.[17][19][20]
  • Monoamine oxidase inhibitors allow reuptake of biogenic amine neurotransmitters from the synapse, but inhibit an enzyme which normally destroys (metabolizes) some of the transmitters after their reuptake. More of the neurotransmitters (especially serotonin, noradrenaline and dopamine) are available for release into synapses. MAOIs take several weeks to alleviate the symptoms of depression.[17][19][21][22]

Although changes in neurochemistry are found immediately after taking these antidepressants, symptoms may not begin to improve until several weeks after administration. Increased transmitter levels in the synapse alone does not relieve the depression or anxiety.[17][19][22]

Cholinergic system

[edit]

The cholinergic system consists of projection neurons from the pedunculopontine nucleus, laterodorsal tegmental nucleus, and basal forebrain and interneurons from the striatum and nucleus accumbens. It is not yet clear whether acetylcholine as a neuromodulator acts through volume transmission or classical synaptic transmission, as there is evidence to support both theories. Acetylcholine binds to both metabotropic muscarinic receptors (mAChR) and the ionotropic nicotinic receptors (nAChR). The cholinergic system has been found to be involved in responding to cues related to the reward pathway, enhancing signal detection and sensory attention, regulating homeostasis, mediating the stress response, and encoding the formation of memories.[23][24]

GABA

[edit]
GABA nomenclature example

Gamma-aminobutyric acid (GABA) has an inhibitory effect on brain and spinal cord activity.[17] GABA is an amino acid that is the primary inhibitory neurotransmitter for the central nervous system (CNS). It reduces neuronal excitability by inhibiting nerve transmission. GABA has a multitude of different functions during development and influences the migration, proliferation, and proper morphological development of neurons. It also influences the timing of critical periods and potentially primes the earliest neuronal networks. There are two main types of GABA receptors: GABAa and GABAb. GABAa receptors inhibit neurotransmitter release and/or neuronal excitability and are a ligand-gated chloride channel. GABAb receptors are slower to react due to a GCPR that acts to inhibit neurons. GABA can be the culprit for many disorders ranging from schizophrenia to major depressive disorder because of its inhibitory characteristics being dampened.[25][26][27]

Neuropeptides

[edit]
Main article: Neuropeptide

Neuropeptides are small proteins used for communication in the nervous system. Neuropeptides represent the most diverse class of signaling molecules, and vary considerably between animals. There are 90 known genes that encode human neuropeptide precursors. In the fruit fly Drosophila there are ~50 known genes encoding precursors,[28] and in the worm C. elegans 120 genes specify more than 250 neuropeptides.[29] Most neuropeptides bind to G-protein coupled receptors, however some neuropeptides directly gate ion channels[30] or act through kinase receptors.[31]

  • Opioid peptides – a large family of endogenous neuropeptides that are widely distributed throughout the central and peripheral nervous system. Opiate drugs such as heroin and morphine act at the receptors of these neurotransmitters.[32][33]
  1. Endorphins
  2. Enkephalins
  3. Dynorphins

Neuromuscular systems

[edit]

Neuromodulators may alter the output of a physiological system by acting on the associated inputs (for instance, central pattern generators). However, modeling work suggests that this alone is insufficient,[34] because the neuromuscular transformation from neural input to muscular output may be tuned for particular ranges of input. Stern et al. (2007) suggest that neuromodulators must act not only on the input system but must change the transformation itself to produce the proper contractions of muscles as output.[34]

Volume transmission

[edit]

Neurotransmitter systems are systems of neurons in the brain expressing certain types of neurotransmitters, and thus form distinct systems. Activation of the system causes effects in large volumes of the brain, called volume transmission.[35] Volume transmission is the diffusion of neurotransmitters through the brain extracellular fluid released at points that may be remote from the target cells with the resulting activation of extra-synaptic receptors, and with a longer time course than for transmission at a single synapse.[36] Such prolonged transmitter action is called tonic transmission, in contrast to the phasic transmission that occurs rapidly at single synapses.[37][38]

Tonic Transmission

[edit]

There are three main components of tonic transmission: Continued release, sustained release, and baseline regulation. In the context of neuromodulation, continuous release is responsible for releasing neurotransmitters/neuromodulators at a constant low level from glial cells and tonic active neurons. Sustained Influence provides long-term stability to the entire process, and baseline regulation ensures that the neurons are in a continued state of readiness to respond to any signals. Acetylcholine, noradrenaline, dopamine, norepinephrine, and serotonin are some of the main components in tonic transmission to mediate arousal and attention.[39]

Phasic Transmission

[edit]

There are three main components of phasic transmission: burst release, transient effects, and stimulus-driven effects. As the name suggests, burst release is in charge of releasing neurotransmitters/neuromodulators in intense, acute bursts. Transient effects create acute momentary adjustments in neural activity. Lastly, as the name suggests, stimulus-driven effects react to sensory input, external stressors, and reward stimuli, which involve dopamine, norepinephrine, and serotonin.[40]

Types of Neuromodulation Therapies and Treatments

[edit]
Main article: Neurotherapy

The term Neuromodulation is also known in medicine as a targeted artificial modification of neuronal activity through the delivery of chemical agents or electroceutical stimulation to specific neurological parts (see more in the wikiarticle Neuromodulation (medicine)).[41]

Invasive and non-invasive treatment methods form a field of medicine called neurotherapy. There are two main categories for neuromodulation therapy: chemical and electroceutical. The noninvasive electroceutical neurotherapy consists of five techniques:[42]

  • Photonics neurostimulation through the image-forming vision pathways and skin irradiation. This technique is known as Light therapy, and also known as Phototherapy or Luxtherapy. It refers to the body's exposure to intensive electrical light at managed wavelengths to treat different diseases: Depression, Chronic pain, Post-traumatic stress disorder, and Insomnia.[43][42]
  • Transcranial laser radiation refers to directional low-power and high-fluence monochromatic or quasimonochromatic light radiation, also known as photobiomodulation (PBM).[44][42]
  • Transcranial electric current and magnetic field stimulations;[42]
  • Low-frequency sound stimulations, including vibroacoustic therapy (VAT) and rhythmic auditory stimulation (RAS).[45][46][42]
  • Acoustic photonic intellectual neurostimulation (APIN). It applies features of natural neurostimulation during pregnancy scaled on specific patients. Three therapeutic agents cause oxygenation of neuronal tissues, release of adenosine-5′-triphosphate proteins, and neuronal plasticity. This method shows significant results in chronic pain management in various conditions.[47][48][49]

Electrical Neuromodulator Therapies

[edit]

Electrical neuromodulation has three subcategories: deep brain, spinal cord, and transcranial, each aiming to treat specific conditions. Deep brain stimulation involves electrodes being surgically implanted into specific sections of the brain that are commonly responsible for movement and motor control deficiencies and disorders like Parkinson's and tremors. Spinal cord stimulation works by being placed near the spinal cord to send electrical signals through the body to treat various forms of chronic pain like lower back pain and CRPS. This form of neuromodulator treatment is considered one of the more high-risk treatments because of its manipulation near the spinal cord. Transcranial magnetic stimulation is slightly different in that it utilizes a magnetic field to generate electrical currents throughout the brain. This treatment is widely used to remedy various mental health conditions like depression, obsessive-compulsive disorder, and other mood disorders.[50]

Neuromodulation is often used as a treatment mechanism for moderate to severe migraines by way of nerve stimulation. These treatments work by utilizing the basic ascending pathways. There are three main modes. It works by connecting a device to the body that sends electrical pulses directly to the affected site (Transcutaneous Electrical Nerve Stimulation), directly to the brain (invasive electrical Neurotherapy techniques), or by holding a device close to the neck that works to block pain signals modulation from the PNS to the CNS.[51][52] and sends two of the most notable modes of that treatment, which are electrical and magnetic stimulation. Electrical nerve stimulation and some of the characterizations include transcranial alternating stimulation and transcranial direct current stimulation. The other is magnetic stimulation, which includes single pulse and repetitive transcranial stimulation.[citation needed]

Chemical Neuromodular Therapies

[edit]

Chemical neuromodulation mostly consists of collaborating natural and artificial chemical substances to treat various conditions. It uses both invasive and non-invasive modes of treatment, including pumps, injections, and oral medications. This mode of treatment can be used to manage immune responses like inflammation, mood, and motor disorders.[53]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Neuromodulation

View on Grokipedia
from Grokipedia
Neuromodulation encompasses both physiological processes and therapeutic interventions that alter neural activity within the . In , it refers to the of neural and synaptic function by extrinsic or intrinsic neuromodulatory substances, which modify the of synaptic transmission, neuronal excitability, and overall network in response to behavioral states or task demands. Therapeutically, neuromodulation is defined as the alteration of activity through targeted delivery of stimuli, such as electrical or chemical agents, to specific neurological sites in the central, peripheral, or autonomic nervous systems, aiming to achieve clinical benefits for various disorders. In physiological contexts, neuromodulation plays a critical role in adapting function to environmental and internal changes, influencing processes like , learning, mood, and arousal. Key neuromodulators include monoamines such as , serotonin, and norepinephrine, as well as , , and various neuropeptides, which are released from specialized neurons and diffuse widely to affect multiple targets over extended timescales compared to fast synaptic transmission. These substances enable flexible neural processing by altering conductances, second messenger systems, and , thereby fine-tuning information flow across brain circuits. Dysfunctions in endogenous neuromodulation are implicated in disorders like , depression, and , highlighting its foundational importance in . Therapeutic neuromodulation has evolved into a multidisciplinary field combining , , and medicine, with applications spanning management, , psychiatric conditions, and . Common techniques include invasive methods like deep brain stimulation (DBS), which delivers electrical pulses via implanted electrodes to modulate dysfunctional circuits in conditions such as and , and non-invasive approaches like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) for treating depression and rehabilitation. stimulation and represent peripheral neuromodulation strategies effective for and , respectively, while emerging bioelectronic medicines target autonomic functions for and . These interventions restore or normalize aberrant neural activity, offering alternatives to pharmacological treatments with potentially fewer systemic side effects, and continue to advance through innovations in device miniaturization and closed-loop systems.

Fundamentals

Definition and Scope

Neuromodulation is the physiological process by which neurons release neuromodulators—such as monoamines and neuropeptides—to modify the excitability, synaptic efficacy, or firing patterns of broad populations of neurons over extended timescales, distinct from the rapid, point-to-point signaling of classical . This process enables neural circuits to adapt dynamically, reconfiguring their output to support behavioral flexibility across diverse contexts. The scope of neuromodulation extends to both the central and peripheral nervous systems, where it regulates essential functions including , mood, learning, and . Endogenous neuromodulators, including biogenic amines like , serotonin, and norepinephrine, as well as peptides, diffuse through extracellular spaces via volume transmission to influence widespread neural activity, contrasting with the localized, fast actions of neurotransmitters such as glutamate or GABA. For instance, neuromodulation governs neural circuits in sleep-wake transitions, reward processing, and , ensuring coordinated responses to environmental demands. At the molecular level, neuromodulators predominantly engage G-protein-coupled receptors (GPCRs), triggering intracellular second messenger cascades—such as those involving cyclic AMP (cAMP) or (IP3)—that phosphorylate ion channels, receptors, or synaptic proteins to alter neuronal properties. These mechanisms allow for persistent changes in circuit dynamics, promoting plasticity and state-dependent modulation without directly evoking action potentials.

Historical Development

The foundations of neuromodulation trace back to early 20th-century investigations into chemical . In , demonstrated that stimulation of the in isolated hearts released a substance—later identified as —that slowed the heartbeat of a second heart, providing the first evidence for chemical synaptic transmission. This discovery shifted the field from electrical to chemical signaling paradigms. Building on this, the mid-20th century saw the identification of monoamines as key signaling molecules; notably, in the 1950s, established as an independent in the , distinct from its role as a norepinephrine precursor, through pharmacological assays showing its depletion by and restoration by . The term "neuromodulation" emerged from Edward A. Kravitz's work in the early 1970s describing the modulatory effects of amines, such as and serotonin, on excitatory and inhibitory transmission at lobster neuromuscular junctions, highlighting their role in altering synaptic efficacy rather than directly eliciting responses. The 1970s marked a pivotal recognition of neuromodulation's slower dynamics. Researchers observed slow synaptic potentials lasting seconds to minutes, mediated by monoamines and peptides, which contrasted with fast ionotropic transmission and influenced neuronal excitability over extended periods. Concurrently, Luigi F. Agnati and Kjell Fuxe advanced the concept of volume transmission in the 1970s and 1980s, proposing that monoamines like diffuse through extracellular spaces and to act on distant targets via varicose fibers, as evidenced by fluorescence histochemistry and revealing non-synaptic transmitter-receptor mismatches. Advances in the late integrated imaging and modeling techniques. In the , positron emission tomography () enabled in vivo mapping of dopamine receptors using radioligands like [11C]methylspiperone, allowing noninvasive visualization of dopaminergic systems in humans and baboons, which linked receptor densities to neuropsychiatric conditions. By the , computational models began elucidating neuromodulation's role in plasticity; for instance, simulations of dopamine's influence on demonstrated how it gates synaptic changes in decision-making circuits, providing a framework for understanding adaptive behaviors. In the and , large-scale initiatives like the have connected neuromodulatory networks to brain disorders, using diffusion MRI and to map altered connectivity in conditions such as and depression, where and serotonergic imbalances disrupt circuit dynamics. Recent efforts emphasize multi-omics approaches to dissect modulator interactions; for example, integrated genomic, transcriptomic, and proteomic analyses in have revealed how serotonin and pathways intersect with inflammatory and epigenetic factors, informing personalized therapeutic strategies.

Biological Mechanisms

Distinction from Classical Neurotransmission

Classical synaptic , often referred to as fast , involves the rapid release of neurotransmitters from presynaptic terminals into a narrow synaptic cleft, where they bind to ionotropic receptors on the postsynaptic , leading to quick changes in that can directly trigger action potentials. This process operates on very short timescales, typically 1-10 milliseconds, and is highly localized, occurring point-to-point between precisely connected neurons. For instance, glutamate binding to receptors exemplifies this mechanism, facilitating excitatory postsynaptic potentials through direct ion flux. In contrast, neuromodulation employs slower signaling pathways, where neuromodulators are released from varicosities or synaptic terminals to diffuse more broadly, influencing receptors on multiple neurons over larger volumes. These effects are mediated primarily by metabotropic G-protein-coupled receptors (GPCRs), which activate intracellular second messenger systems rather than directly opening ion channels, resulting in timescales ranging from hundreds of milliseconds to hours. This diffuse mode, often involving volume transmission, allows neuromodulators to exert widespread influence without strict synaptic alignment. Functionally, classical neurotransmitters drive immediate neural communication by eliciting fast excitatory or inhibitory responses that propagate signals across circuits. Neuromodulators, however, do not typically evoke direct postsynaptic potentials; instead, they fine-tune neuronal and synaptic properties by altering excitability, synaptic efficacy, or plasticity through mechanisms like . For example, activation of GPCRs can increase cyclic AMP (cAMP) levels, leading to of ion channels such as hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, which modulates intrinsic neuronal excitability without generating action potentials. A notable illustration of these distinctions is the dual role of , which acts as a fast at the via ionotropic nicotinic receptors to directly trigger , but functions as a neuromodulator in the through slower metabotropic muscarinic receptors, influencing and plasticity. Similarly, enhances [long-term potentiation](/page/Long-term_p potentiation) (LTP) in the hippocampus by gating synaptic strengthening mechanisms via D1-like receptors, without causing direct neuronal excitation. These examples highlight how neuromodulation adapts circuit dynamics over extended periods, complementing the rapid signaling of classical neurotransmission.

Volume Transmission

Volume transmission refers to the non-synaptic of neuromodulators from release sites to receptors located at considerable distances, facilitating widespread modulation of neural circuits rather than point-to-point signaling. This process allows neuromodulators, such as monoamines and neuropeptides, to act as paracrine signals in the , influencing multiple target cells simultaneously. The concept was first proposed by Agnati et al. in 1986 as a complement to traditional wired synaptic transmission, highlighting its role in slower, more diffuse forms of intercellular communication in the . Neuromodulators are released from axonal varicosities—beaded swellings along axons that lack the specialized synaptic clefts of classical synapses—enabling free into the . This follows concentration gradients, with the spread of molecules governed by factors including molecular size, , and of the diffusion path. Clearance mechanisms, such as via transporters like the (DAT), rapidly terminate signaling by removing neuromodulators from the extracellular milieu, while the acts as a structural barrier that can impede or channel , influencing the spatial extent of the signal. Physiologically, volume transmission enables the integration of neuromodulatory signals across extended neural populations, such as modulating activity throughout cortical layers to coordinate broader circuit functions like or . Extrasynaptic receptors, including D2 autoreceptors on terminals, sense ambient neuromodulator levels in the and provide feedback to regulate release rates, thereby maintaining and preventing overstimulation. This diffuse signaling contrasts with the localized precision of synaptic transmission, allowing neuromodulators to exert prolonged, integrative effects on network excitability. Supporting evidence for volume transmission derives from microdialysis techniques, which measure extracellular neuromodulator levels and reveal that released in the can diffuse over distances of 100–500 μm, encompassing volumes far exceeding single synaptic domains and influencing remote neuronal ensembles. These findings underscore the spatial scale of neuromodulatory influence, consistent with observations of non-synaptic release sites and extrasynaptic receptor .

Neuromodulatory Systems

Noradrenergic System

The noradrenergic system, centered on norepinephrine (NE) as its primary , originates predominantly from the (LC), a compact nucleus of noradrenergic neurons located bilaterally in the pontine tegmentum of the brainstem. The LC sends extensive axonal projections throughout the , including dense innervations to the , hippocampus, , , and , enabling widespread modulation of neural activity. These projections interact with postsynaptic adrenergic receptors, primarily α1- and α2-adrenoceptors, which are G-protein-coupled, and β-adrenoceptors, which are also G-protein-coupled but mediate distinct signaling pathways such as cyclic AMP production. Functionally, the noradrenergic system plays a critical role in enhancing vigilance and , facilitating adaptive responses to environmental demands through LC-mediated NE release. It contributes to the stress response by activating sympathetic-like mechanisms that heighten physiological readiness, while also supporting , particularly in the hippocampus, where NE strengthens during emotionally salient events. Additionally, the system modulates by improving signal-to-noise ratios in cortical and subcortical circuits, achieved through variations in LC firing patterns that prioritize relevant stimuli over background noise. Pharmacologically, the noradrenergic system is targeted by various agents that alter NE availability or receptor activity. α2-Adrenergic agonists like reduce NE release by providing presynaptic feedback inhibition at α2 autoreceptors on LC neurons, often used to manage hyperactivity. In contrast, α1-antagonists such as block postsynaptic α1-receptors, attenuating NE-mediated vasoconstriction and arousal effects. Selective norepinephrine reuptake inhibitors (NRIs), exemplified by , enhance synaptic NE levels by blocking its reuptake via the norepinephrine transporter, proving effective in treating depression by bolstering mood regulation. Dysfunctions in the noradrenergic system are implicated in several psychiatric and neurodegenerative conditions. Hypoactivity or dysregulation contributes to attention-deficit/hyperactivity disorder (ADHD), where impaired NE signaling disrupts vigilance and executive function, as evidenced by the efficacy of NRIs and stimulants that boost NE transmission. Similarly, excessive LC-NE activity is linked to anxiety disorders, amplifying threat detection and autonomic arousal. In , early LC degeneration leads to NE depletion, exacerbating pathology, , and cognitive decline; recent 2025 research highlights potential neuroprotective strategies targeting LC restoration to mitigate these effects.

Dopaminergic System

The dopaminergic system originates primarily from midbrain nuclei, including the pars compacta (SNpc) and the (VTA), which give rise to key pathways such as the , , and projections. The innervates the dorsal , facilitating motor control, while the targets the and associated limbic structures to modulate reward processing, and the extends to the , influencing . Dopamine release in these pathways often occurs via volume transmission in regions like the , allowing diffuse modulation beyond synaptic clefts. Dopamine exerts its effects through five receptor subtypes divided into D1-like (D1 and D5) and D2-like (D2, D3, D4) families, which couple to distinct G-protein signaling pathways. D1-like receptors are primarily excitatory, activating to increase cyclic AMP levels and enhance neuronal excitability, whereas D2-like receptors are generally inhibitory, inhibiting or modulating potassium channels to reduce firing rates. This dichotomy enables balanced modulation of downstream circuits, with D1-like receptors often promoting locomotion and , and D2-like receptors regulating inhibition and autoregulation of dopamine release. In terms of functions, the dopaminergic system is central to reward prediction error signaling, where phasic bursts of dopamine neurons encode discrepancies between expected and actual rewards to drive learning and . These phasic signals, lasting 100-200 milliseconds, highlight salient environmental stimuli, promoting motivation and goal-directed behavior, while tonic levels maintain baseline arousal. Additionally, the supports motor initiation by facilitating movement selection and execution through direct and indirect striatal pathways. Pharmacologically, dopamine agonists like , a precursor converted to in the , are the cornerstone for treating deficits, restoring motor function in conditions of depletion by increasing striatal availability. Conversely, antipsychotics such as act as D2 receptor antagonists, with high binding affinity (Ki ≈ 0.35 nM) to block hyperactive signaling and alleviate positive symptoms of . itself binds D2 receptors with moderate affinity in the high-affinity state (Ki ≈ 20 nM), underscoring the precision of antagonists in therapeutic targeting. Dysfunctions in the system underlie several disorders, notably , characterized by the progressive loss of SNpc neurons leading to nigrostriatal denervation and motor impairments like bradykinesia. In , mesolimbic hyperactivity contributes to positive symptoms such as hallucinations, driven by excessive release in limbic regions. Recent advances include 2025 trials aimed at dopaminergic restoration; for instance, a Phase I trial using human embryonic stem cell-derived dopaminergic neurons demonstrated safe engraftment and functional production in Parkinson's patients, improving motor scores without tumor formation. Similarly, a Phase I/II trial with induced pluripotent stem cell-derived dopaminergic progenitors reported sustained neuron survival and release up to 24 months post-transplantation.

Serotonergic System

The serotonergic system originates primarily from clusters of neurons in the , located along the midline of the from the medulla to the . These nuclei, including the (DRN) and median raphe nucleus (MRN), project extensively to the structures such as the cortex, hippocampus, and , as well as to the and , forming a diffuse network that modulates widespread neural activity. The system features over 14 receptor subtypes classified into seven families (5-HT1 through 5-HT7), with the majority, particularly the 5-HT1 and 5-HT5 families, coupling to inhibitory Gi/o proteins that suppress activity and reduce cyclic AMP levels. Serotonin (5-HT) released from these projections plays a key role in mood regulation by influencing emotional processing in limbic regions, promoting emotional stability and resilience to stress. It also contributes to impulse control, dampening impulsive behaviors through inhibitory effects on prefrontal circuits, and helps maintain circadian rhythms by synchronizing activity with environmental light cues. Additionally, serotonergic terminals in the modulate and anxiety, with reduced activity linked to heightened aggressive responses and states in animal models. Pharmacologically, selective serotonin reuptake inhibitors (SSRIs) like target the (SERT), blocking 5-HT reuptake into presynaptic neurons and thereby elevating extracellular 5-HT levels; exhibits high affinity for SERT with inhibition kinetics reflecting SERT's endogenous substrate affinity (Km ≈ 0.3 μM). Psychedelics such as act as agonists at 5-HT2A receptors, particularly in cortical pyramidal neurons, inducing altered perception and through downstream signaling cascades like β-arrestin recruitment. These interventions enhance serotonergic transmission, with SSRIs providing sustained elevation and psychedelics offering acute, receptor-specific activation. Dysfunctions in the serotonergic system are implicated in via the low 5-HT hypothesis, which posits that diminished serotonergic signaling contributes to mood deficits, as evidenced by the efficacy of SSRIs in restoring balance. In obsessive-compulsive disorder (OCD), aberrant 5-HT signaling in cortico-striatal circuits underlies compulsive behaviors, with high-dose SSRIs alleviating symptoms by normalizing impulse control. By 2025, advances in rapid-acting s, such as 5-HT1A biased agonists like NLX-101, have targeted specific serotonergic circuits to produce effects within hours, offering alternatives to traditional SSRIs for .

Additional Neuromodulators

Cholinergic System

The system exerts dual roles in the , functioning as both a fast-acting and a key neuromodulator, with its modulatory influences primarily arising from widespread projections originating in the and . neurons in the , particularly within the of Meynert, send diffuse, branched projections to the , hippocampus, and other subcortical structures, enabling broad regulation of cortical activity. In the , cells in the pedunculopontine tegmental nucleus (PPTg) and laterodorsal tegmental nucleus (LDT) project to thalamic, hypothalamic, and targets, contributing to and sleep-wake transitions. These projections release (ACh), which binds to nicotinic receptors—ionotropic ligand-gated channels that permit rapid cation influx for excitatory synaptic transmission—and muscarinic receptors, G-protein-coupled metabotropic receptors that trigger slower intracellular signaling cascades. In its neuromodulatory capacity, the cholinergic system plays essential roles in , learning, and by dynamically altering neuronal excitability and synaptic efficacy across cortical networks. Activation of M1 muscarinic receptors on pyramidal neurons enhances intrinsic excitability through suppression of conductances and promotes (LTP), a cellular correlate of learning, by facilitating calcium-dependent signaling pathways. This modulation sharpens and supports adaptive behaviors during tasks requiring focused . cholinergic projections are particularly vital for promoting rapid eye movement (REM) sleep, where increased ACh release desynchronizes cortical EEG activity and inhibits motor tone via interactions with pontine circuits. Overall, these functions underscore the system's capacity to coordinate state-dependent plasticity, with tonic ACh release sustaining baseline vigilance and phasic bursts driving task-specific enhancements. Pharmacological interventions targeting the cholinergic system leverage its receptors and synthetic enzymes to address cognitive impairments. Acetylcholinesterase inhibitors, such as donepezil, elevate synaptic ACh levels by preventing its breakdown, thereby improving attention and memory in patients through enhanced muscarinic and nicotinic signaling. Muscarinic antagonists like block these receptors centrally and peripherally, reducing vestibular-induced nausea and serving as a standard treatment for . For subtype-specific modulation, partial agonists at α7 nicotinic receptors have been investigated to enhance cognitive domains like by amplifying transmission, though advanced clinical trials have not confirmed consistent efficacy. Cholinergic dysfunctions prominently feature in neurodegenerative and psychiatric disorders, with selective neuronal loss disrupting modulatory balance. In , degeneration of cholinergic neurons leads to profound ACh deficits, correlating with cognitive decline and forming the basis of the cholinergic hypothesis. Similarly, in , reduced expression of muscarinic and nicotinic receptors impairs attentional gating and , as evidenced by and postmortem studies. As of 2025, research continues to explore α7 nicotinic agonists for schizophrenia despite challenges in advanced clinical trials.

GABAergic and Glutamatergic Modulation

GABAergic modulation extends beyond phasic synaptic events to include tonic inhibition mediated by extrasynaptic GABAA receptors, which are particularly prominent in the hippocampus and incorporate the δ-subunit for sustained control of neuronal excitability. These receptors respond to ambient GABA levels, generating a persistent inhibitory conductance that helps maintain circuit by dampening overall network activity without relying on discrete synaptic inputs. Neurosteroids, such as , act as positive allosteric modulators of these δ-containing GABAA receptors, enhancing tonic inhibition and thereby reducing neuronal excitability in a region-specific manner. In the context of anxiety regulation, tonic inhibition in limbic structures like the plays a critical role, where its disruption leads to heightened fear responses and . Glutamatergic modulation involves metabotropic glutamate receptors (mGluR1-8), a family of G-protein-coupled receptors that fine-tune neuronal excitability through second-messenger signaling pathways, influencing and network stability independent of ionotropic fast transmission. These receptors respond to glutamate spillover or ambient levels, which are regulated by transporters such as EAAT2 on , thereby modulating mood-related circuits in the and . Ambient glutamate dynamics, in particular, contribute to circuit by preventing while supporting adaptive changes in connectivity, as seen in synaptic scaling mechanisms where postsynaptic density adjusts globally to preserve firing rates across the . Dysfunctions in these systems underlie several neuropsychiatric disorders; for instance, hypoactivity of tonic inhibition is implicated in , where reduced extrasynaptic function leads to unchecked hyperexcitability and propagation in hippocampal networks. Similarly, hypofunction, particularly involving impaired signaling and elevated ambient glutamate clearance deficits, contributes to by disrupting prefrontal dopamine-glutamate interactions and cognitive processing. Advances in precision medicine as of 2025 include subtype-selective allosteric modulators targeting δ-GABAA receptors (e.g., derivatives like ) for anxiety and mood disorders such as , and preclinical studies suggest mGluR2/3 positive allosteric modulators may restore balance in , though clinical trials have shown mixed results.

Neuropeptides and Endocannabinoids

Neuropeptides serve as key neuromodulators in the , often co-released with classical neurotransmitters from large dense-core vesicles in response to high-frequency or sustained neuronal activity. This co-release enables neuropeptides to exert slower, longer-lasting effects on synaptic transmission and neuronal excitability compared to fast-acting transmitters stored in small clear vesicles. Unlike classical , neuropeptide signaling frequently involves volume transmission, where peptides diffuse over distances of several microns to influence broader neural ensembles. Prominent examples of neuropeptides include , which promotes and by exciting monoaminergic and neurons in the and . , an 11-amino-acid peptide, plays a central role in transmission and sensitization by activating neurokinin-1 receptors on sensory neurons and in the , enhancing nociceptive signaling. Endogenous opioid neuropeptides, such as enkephalins and , mediate analgesia through μ- receptors, inhibiting pathways in the and while also modulating reward circuits, often in concert with for . Endocannabinoids, lipid-derived signaling molecules like 2-arachidonoylglycerol (2-AG) and , function primarily through , where they are synthesized postsynaptically in response to calcium influx and diffuse backward to activate presynaptic CB1 receptors. This activation suppresses the release of neurotransmitters such as glutamate and GABA, facilitating forms of like depolarization-induced suppression of inhibition or excitation. 2-AG, in particular, acts as the primary endocannabinoid for activity-dependent retrograde modulation across various brain synapses. Both neuropeptides and endocannabinoids fine-tune emotional responses, such as and anxiety, by integrating with limbic circuits to regulate stress reactivity and extinction learning. In feeding behavior, and endocannabinoids promote and ; for instance, endocannabinoids enhance orexigenic signaling in the to increase food intake. Their volume diffusion allows modulation over extended spatial scales, influencing network-level dynamics in regions like the and . Endocannabinoids also interact briefly with dopaminergic reward pathways to shape motivational states. Dysfunctions in these systems contribute to neuropsychiatric disorders; CB1 receptor dysregulation disrupts endocannabinoid tone, promoting vulnerability by altering reward sensitivity and impulse control in mesolimbic circuits. Chronic opioid exposure leads to tolerance in neuropeptide-mediated analgesia, involving receptor desensitization and upregulated inflammatory mediators that exacerbate pain hypersensitivity. As of 2025, a of amide hydrolase inhibitors to elevate levels found no significant augmentation of exposure-based for PTSD symptoms compared to therapy alone.

Transmission Modes

Tonic Transmission

Tonic transmission refers to the sustained, low-level release of neuromodulators that maintains baseline states in neural circuits, providing a continuous modulatory tone essential for network stability. This mode of signaling contrasts with more transient forms by operating on longer timescales, typically seconds to minutes, to regulate overall circuit excitability and responsiveness. The mechanism of tonic transmission involves continuous basal release of neuromodulators from varicosities—specialized swellings along unmyelinated axons of neuromodulatory neurons—without reliance on traditional synaptic vesicles or action potential-evoked bursts. These varicosities enable diffuse of the neuromodulator into the , where it is primarily detected by extrasynaptic receptors located on neuronal somata, dendrites, or even non-neuronal cells. Release rates are tightly regulated by presynaptic autoreceptors, which exert to prevent excessive accumulation, and by high-affinity uptake transporters that rapidly clear the neuromodulator from the synaptic cleft and extracellular milieu; for instance, the (NET) efficiently reuptakes norepinephrine, maintaining low ambient levels. This dynamic balance ensures that tonic levels remain within a narrow physiological range, shaped further by enzymatic degradation and . Functionally, tonic transmission establishes a foundational level of global excitability across neural populations, influencing baseline synaptic efficacy and plasticity thresholds. A representative example is ambient in the , where concentrations of approximately 1–5 nM—measured under resting conditions in models—stabilize performance by preferentially activating D1-like receptors, which exhibit an inverted-U dose-response curve for optimal cognitive function. Such sustained modulation supports persistent neural representations without overwhelming the system, allowing circuits to remain poised for adaptive responses. Tonic neuromodulator levels are commonly measured using microdialysis, a technique that samples over intervals of several minutes to capture steady-state concentrations, revealing basal profiles that reflect ongoing release and clearance dynamics. This method has demonstrated consistent tonic elevations or depletions in various brain regions, providing insights into homeostatic regulation, though it lacks the for detecting rapid fluctuations. Dysregulation of tonic transmission contributes to neuropsychiatric disorders, as seen in depression where reduced tonic serotonin levels impair mood regulation and emotional processing. Low ambient serotonin diminishes postsynaptic signaling through 5-HT1A autoreceptors and transporters, perpetuating a hypoactive state in serotonergic pathways. Tonic transmission often leverages volume transmission for its spatial reach, allowing neuromodulators to influence distant targets via extracellular diffusion.

Phasic Transmission

Phasic transmission refers to the brief, stimulus-evoked release of neuromodulators, characterized by high-amplitude bursts triggered by action potentials in presynaptic terminals, leading to rapid and of nearby receptors. This mode contrasts with tonic transmission by producing transient extracellular concentrations that decay quickly, often within hundreds of milliseconds, due to efficient clearance mechanisms such as by transporters. For instance, in systems, phasic bursts generate transients lasting approximately 100 ms, primarily cleared by the (DAT), which limits spatial spread to tens of micrometers around release sites. Similar dynamics occur in noradrenergic transmission from the (LC), where phasic firing synchronizes across neurons to release norepinephrine in localized bursts. Across neuromodulators like acetylcholine and serotonin, phasic release follows comparable principles, with action potential-driven enabling precise, event-locked signaling.30011-4) Functionally, phasic transmission signals salient events such as novelty or rewards, facilitating adaptive behavioral responses and . In the LC-noradrenergic system, phasic bursts enhance attention shifts by amplifying and orienting responses to unexpected stimuli, as evidenced by increased pupil dilation and cortical linked to these firing patterns. Dopaminergic phasic signals, particularly in the , encode reward prediction errors, promoting by strengthening synapses associated with positive outcomes.00734-X) This mode also drives plasticity mechanisms, such as (LTP); for example, phasic dopamine release coincides with pauses in interneurons to induce LTP at corticostriatal synapses, enabling associative learning. In broader neuromodulatory contexts, phasic acetylcholine transients support by modulating cortical excitability during task-relevant events. Electrophysiological and electrochemical techniques provide key evidence for phasic transmission. Fast-scan cyclic voltammetry (FSCV) detects subsecond peaks reaching micromolar concentrations (up to 1-10 μM) in striatal regions during burst firing, confirming the rapid onset and clearance of these signals. In vivo recordings from LC neurons reveal phasic bursts of 3-10 action potentials at frequencies exceeding 10 Hz, synchronized by shared inputs and correlating with behavioral salience. Computational models, including temporal difference (TD) learning frameworks, integrate these observations by positing phasic as a teaching signal that updates value predictions, with burst activity aligning firing rates to prediction errors for efficient learning. Such evidence underscores phasic transmission's role in dynamic network modulation across species and regions. Dysfunctions in phasic transmission contribute to neuropsychiatric disorders, notably . In cocaine self-administration models, repeated exposure blunts phasic release in the , reducing signaling amplitude by up to 50% and impairing reward sensitivity, which perpetuates . This attenuation disrupts TD error computation, leading to aberrant habit formation as phasic signals fail to reinforce adaptive choices. Similar impairments in LC phasic firing have been linked to attentional deficits in disorders like ADHD, highlighting the conserved vulnerability of phasic modes to pathological alterations.00819-7) Tonic and phasic modes interact dynamically to fine-tune neural signaling. For example, elevated tonic dopamine levels can suppress phasic release through of D2 autoreceptors on neurons, preventing overstimulation and maintaining signaling fidelity. Conversely, phasic bursts can transiently alter local tonic levels, influencing subsequent baseline excitability. This interplay is critical for adaptive behaviors and is disrupted in conditions like and .

Therapeutic Applications

Electrical and Magnetic Stimulation

Electrical and magnetic stimulation techniques represent cornerstone methods in therapeutic neuromodulation, utilizing implanted or external devices to deliver targeted electrical impulses or induced magnetic fields that modulate neural activity in the central and peripheral nervous systems. These approaches are particularly effective for disorders involving dysregulated neural circuits, such as and mood dysregulation, by altering neuronal firing patterns and synaptic transmission without relying on pharmacological agents. (DBS) exemplifies invasive electrical neuromodulation, where electrodes are surgically implanted into specific brain nuclei to deliver high-frequency pulses, while (TMS) offers a non-invasive alternative by generating magnetic fields that induce electrical currents in superficial cortical regions. Both methods have garnered FDA approvals for clinical use, demonstrating their safety and in alleviating symptoms of refractory conditions. Deep brain stimulation for Parkinson's disease targets the subthalamic nucleus (STN) with high-frequency stimulation, typically at 130 Hz, to suppress pathological oscillations and restore balanced . This technique involves implanting leads into the STN connected to a chest-mounted , which delivers continuous biphasic pulses that modulate circuits implicated in pathway dysregulation. The primary mechanism involves high-frequency DBS inducing synaptic depression and altering neuronal firing patterns, effectively inhibiting excessive beta-band activity (13-35 Hz) associated with bradykinesia and rigidity, rather than simple depolarization blockade. FDA approval for DBS was granted in 1997 for unilateral thalamic stimulation to treat , with expansions in 2002 to bilateral STN targeting for advanced Parkinson's symptoms. Transcranial magnetic stimulation, particularly repetitive TMS (rTMS), employs rapidly changing magnetic fields to induce focal electrical currents in the brain, targeting the left (DLPFC) for . High-frequency rTMS (e.g., 10-20 Hz) over the DLPFC enhances cortical excitability and promotes , potentially by increasing transmission and modulating connectivity to alleviate and cognitive deficits. Unlike invasive methods, TMS requires no , with sessions lasting 20-40 minutes over several weeks, and it received FDA clearance in 2008 for in adults. Beyond movement and mood disorders, electrical neuromodulation extends to via (VNS), where an implanted device delivers intermittent pulses to the left to reduce frequency by desynchronizing cortical activity. VNS was FDA-approved in 1997 as an adjunctive therapy for refractory partial-onset seizures in patients over 12 years old, with mechanisms involving afferent projections to nuclei that inhibit epileptogenic foci. For , spinal cord stimulation () involves epidural electrode arrays that deliver low-voltage pulses to the dorsal columns, gating nociceptive signals via the and reducing perceived pain intensity. SCS systems received initial FDA approvals between 1981 and 1984 for intractable trunk and limb pain, with modern iterations providing paresthesia-free stimulation for conditions like failed back surgery syndrome. Recent advancements as of 2025 emphasize closed-loop systems, which adapt stimulation parameters in real-time based on detected neural biomarkers, such as pathological beta oscillations, to optimize therapeutic efficacy and minimize side effects. These adaptive systems, incorporating onboard sensing electrodes, have shown superior motor symptom control in Parkinson's patients compared to continuous stimulation, with clinical trials demonstrating reduced energy consumption and improved in ambulatory settings.

Pharmacological Interventions

Pharmacological interventions in neuromodulation involve the use of chemical agents to modulate systems, primarily by mimicking, enhancing, or inhibiting the activity of endogenous neuromodulators such as , , and norepinephrine, thereby altering neural signaling for therapeutic purposes. These drugs target specific receptor subtypes or transporters to influence synaptic transmission and plasticity in circuits associated with mood, , and . For instance, selective serotonin reuptake inhibitors (SSRIs), such as , block the (SERT), increasing extracellular serotonin levels and enhancing serotonergic signaling across various receptor subtypes like 5-HT1A and 5-HT2A. This mechanism promotes and is foundational in treating disorders involving dysregulated serotonin modulation. Reuptake inhibitors represent a key class of pharmacological agents, including norepinephrine-dopamine reuptake inhibitors (NDRIs) like bupropion, which selectively inhibit the (NET) and (DAT), elevating synaptic levels of these catecholamines without significant serotonergic effects. Bupropion's dual action enhances and noradrenergic transmission in prefrontal and limbic regions, contributing to its efficacy in depression and by modulating reward and motivational pathways. Similarly, serotonin-norepinephrine reuptake inhibitors (SNRIs), such as , inhibit both SERT and NET, providing broader neuromodulation for conditions like where multiple monoamine systems are implicated. These agents typically have half-lives ranging from 5 to 24 hours, allowing once- or twice-daily dosing, though individual vary based on metabolism via enzymes. Agonists and antagonists further refine neuromodulation by directly interacting with receptors; for example, acts as a at postsynaptic 5-HT1A receptors, reducing anxiety by dampening excessive serotonergic hyperactivity in the and hippocampus without the sedative effects of benzodiazepines. In attention-deficit/hyperactivity disorder (ADHD), , a selective inhibitor, increases norepinephrine and indirectly in prefrontal cortex circuits, improving executive function and as evidenced by enhanced activation in the right during cognitive tasks. Clinical applications extend to depression, where SNRIs alleviate symptoms by restoring monoamine balance, though potential side effects include —a potentially life-threatening condition characterized by , autonomic instability, and neuromuscular abnormalities arising from excessive serotonergic activity, particularly when combining multiple agents. As of 2025, advances in pharmacological neuromodulation include psychedelic-assisted therapies, with emerging as a promising agent for through its at 5-HT2A receptors, promoting rapid synaptic remodeling and emotional processing in guided sessions. Clinical trials have demonstrated sustained antidepressant effects lasting up to a year following a single dose, with Pathways' COMP360 formulation showing positive phase 3 results in double-blinded studies, positioning it for potential FDA approval within the next two years. These interventions highlight the shift toward targeted, receptor-specific modulation to address unmet needs in psychiatric care.

Emerging Non-Invasive Techniques

(tDCS) applies weak electrical currents, typically 1-2 mA, via scalp electrodes to modulate neuronal excitability without inducing action potentials. Anodal tDCS enhances cortical activity by subthreshold of the resting , promoting neuronal firing, while cathodal stimulation suppresses it through hyperpolarization. Post-2020 advancements have refined tDCS for cognitive enhancement, with randomized trials demonstrating improved and in healthy adults and individuals with , often with effects lasting beyond the stimulation session. High-definition tDCS configurations achieve more focal targeting, reducing diffuse effects compared to conventional montages. Low-intensity focused ultrasound (LIFU) provides non-invasive access to deep brain regions by delivering acoustic pressure waves that activate mechanosensitive ion channels, such as , to alter neuronal membrane conductance and firing patterns without incision or . Operating at frequencies of 250 kHz to several MHz, LIFU offers millimeter-scale , enabling precise modulation of subcortical structures inaccessible to surface-based methods. Since 2020, clinical studies have validated its neuromodulatory effects, including suppression of aberrant activity in models and enhancement of prefrontal function in tasks, with no reported seizures across trials involving thousands of pulses. In substance use disorders (SUD), repetitive (rTMS), an evolution of classical , targets the to reduce cravings, with meta-analyses of post-2020 trials showing significant decreases in alcohol and cocaine cue reactivity. For obsessive-compulsive disorder (OCD), 2025 clinical trials are evaluating non-invasive modulation of alpha oscillations via transcranial alternating current stimulation (tACS) to normalize frontostriatal circuits, yielding preliminary reductions in Yale-Brown Obsessive Compulsive Scale scores. These techniques complement established electrical methods by emphasizing portability and personalization. Recent innovations include battery-powered portable tDCS devices that facilitate home-based administration, achieving comparable efficacy to clinic settings in cognitive rehabilitation without increased risks. Artificial intelligence-driven protocols optimize stimulation parameters by integrating real-time EEG feedback, boosting response rates in cognitive tasks by up to 20% in personalized applications. Funding from the has accelerated these developments, supporting tools for enhanced spatiotemporal precision in non-invasive neuromodulation.

References

  1. https://link.springer.com/referenceworkentry/10.1007/978-1-0716-1006-0_787
  2. https://www.neuromodulation.com/neuromodulation-defined
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3724171/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC11748337/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC3482119/
  6. https://www.nature.com/articles/s41380-024-02608-3
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC4252488/
  8. https://www.nobelprize.org/prizes/medicine/1936/loewi/lecture/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC2824994/
  10. https://pubmed.ncbi.nlm.nih.gov/1295679/
  11. https://pubmed.ncbi.nlm.nih.gov/19853007/
  12. https://www.science.org/doi/10.1126/science.6604315
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC2866366/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC7847552/
  15. https://www.aginganddisease.org/EN/10.14336/AD.2025.1075
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC7530271/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC11540752/
  18. https://www.sciencedirect.com/topics/neuroscience/neuromodulation
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC8572156/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC3466476/
  21. https://www.sciencedirect.com/science/article/pii/S0959438818301041
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC4173289/
  23. https://www.frontiersin.org/journals/neuroanatomy/articles/10.3389/fnana.2018.00001/full
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4108583/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC2713687/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC2687936/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC4969192/
  28. https://www.ncbi.nlm.nih.gov/books/NBK540977/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7873441/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC8418349/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6742544/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC2657197/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC3181684/
  34. https://www.ncbi.nlm.nih.gov/books/NBK107205/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4699255/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC10149815/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC12402774/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC12409474/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC4816693/
  40. https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/dopaminergic-pathways
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC3479149/
  42. https://www.ncbi.nlm.nih.gov/books/NBK538242/
  43. https://www.sciencedirect.com/science/article/pii/S0306452214005843
  44. https://www.nature.com/articles/s42003-022-03434-5
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC4760620/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC5549862/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC8066851/
  48. https://www.ncbi.nlm.nih.gov/books/NBK482140/
  49. https://www.nature.com/articles/1395694
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC8071183/
  51. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00025/full
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC4032934/
  53. https://www.nature.com/articles/s41586-025-08845-y
  54. https://www.nature.com/articles/s41586-025-08700-0
  55. https://www.ncbi.nlm.nih.gov/books/NBK544359/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC3120045/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC6235773/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC4414735/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC11421740/
  60. https://www.sciencedirect.com/science/article/pii/S0006322398001395
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC9826732/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC9427694/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC2739988/
  64. https://pubmed.ncbi.nlm.nih.gov/30685771/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC3638388/
  66. https://www.sciencedirect.com/science/article/abs/pii/B978044464125000044X
  67. https://pubmed.ncbi.nlm.nih.gov/40890135/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC12124396/
  69. https://www.nature.com/articles/s41598-021-88374-6
  70. https://www.ncbi.nlm.nih.gov/books/NBK557825/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC2745329/
  72. https://www.mdpi.com/2076-3425/12/7/890
  73. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01402/full
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC3648782/
  75. https://www.ncbi.nlm.nih.gov/books/NBK554397/
  76. https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70061
  77. https://www.sciencedirect.com/science/article/abs/pii/S0022356524308730
  78. https://www.nature.com/articles/s41380-025-03023-y
  79. https://pubmed.ncbi.nlm.nih.gov/33834705/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC2075167/
  81. https://pubmed.ncbi.nlm.nih.gov/14623958/
  82. https://www.jneurosci.org/content/32/25/8611
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC2904507/
  84. https://www.nature.com/articles/s41537-017-0037-1
  85. https://www.sciencedirect.com/science/article/pii/S0092867408012981
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC3150203/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC4363164/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC11872799/
  89. https://www.nature.com/articles/s41398-024-03194-2
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC9671847/
  91. https://www.sciencedirect.com/science/article/abs/pii/S0891061811000172
  92. https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2013.00028/full
  93. https://www.ncbi.nlm.nih.gov/books/NBK554583/
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC6826828/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC3517813/
  96. https://www.cell.com/neuron/pdf/S0896-6273%2812%2900855-0.pdf
  97. https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2022.1023541/full
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC7605023/
  99. https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2011.00057/full
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC4652927/
  101. https://www.spandidos-publications.com/10.3892/etm.2021.10437
  102. https://www.nature.com/articles/s41386-025-02128-w
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC3429030/
  104. https://www.frontiersin.org/journals/neural-circuits/articles/10.3389/fncir.2018.00051/full
  105. https://www.jneurosci.org/content/31/37/13046
  106. https://www.sciencedirect.com/science/article/abs/pii/S0361923001006165
  107. https://www.sciencedirect.com/science/article/abs/pii/S0741832906000401
  108. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1335474/full
  109. https://pubs.acs.org/doi/10.1021/ac0693722
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC4047678/
  111. https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-016-1025-0
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC3725633/
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC2713129/
  114. https://www.nature.com/articles/s41593-024-01755-8
  115. https://www.nature.com/articles/s41467-022-28950-0
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699581/
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC4311885/
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC8107188/
  119. https://www.nature.com/articles/s41598-019-56884-z
  120. https://www.pnas.org/doi/10.1073/pnas.1010654108
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC6629510/
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC2896866/
  123. https://pmc.ncbi.nlm.nih.gov/articles/PMC514842/
  124. https://www.mayoclinic.org/diseases-conditions/depression/in-depth/snris/art-20044970
  125. https://www.ncbi.nlm.nih.gov/books/NBK531477/
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC6867141/
  127. https://my.clevelandclinic.org/health/diseases/17687-serotonin-syndrome
  128. https://www.nature.com/articles/d41591-025-00062-4
  129. https://www.mdpi.com/2076-3425/14/4/354
  130. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1667100/full
  131. https://www.the-innovation.org/article/doi/10.59717/j.xinn-life.2025.100150
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC11700779/
  133. https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.046679
  134. https://www.nature.com/articles/s41598-025-16407-5
  135. https://www.nature.com/articles/s41386-023-01776-0
  136. https://www.brainstimjrnl.com/article/S1935-861X%2825%2900188-3/fulltext
  137. https://onlinelibrary.wiley.com/doi/10.1155/2023/9958884
  138. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2813623
  139. https://pmc.ncbi.nlm.nih.gov/articles/PMC11353063/
  140. https://www.nimh.nih.gov/funding/grant-writing-and-application-process/concept-clearances/2019/brain-initiative-non-invasive-neuromodulation-new-tools-and-techniques-for-spatiotemporal-precision
Add your contribution
Related Hubs
User Avatar
No comments yet.